作者
Joseph P McEvoy, Jeffrey A Lieberman, T Scott Stroup, Sonia M Davis, Herbert Y Meltzer, Robert A Rosenheck, Marvin S Swartz, Diana O Perkins, Richard SE Keefe, Clarence E Davis, Joanne Severe, John K Hsiao, Catie Investigators
发表日期
2006/4
期刊
American Journal of Psychiatry
卷号
163
期号
4
页码范围
600-610
出版商
American Psychiatric Association
简介
Objective
When a schizophrenia patient has an inadequate response to treatment with an antipsychotic drug, it is unclear what other antipsychotic to switch to and when to use clozapine. In this study, the authors compared switching to clozapine with switching to another atypical antipsychotic in patients who had discontinued treatment with a newer atypical antipsychotic in the context of the Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE) investigation.
Method
Ninety-nine patients who discontinued treatment with olanzapine, quetiapine, risperidone, or ziprasidone in phase 1 or 1B of the trials, primarily because of inadequate efficacy, were randomly assigned to open-label treatment with clozapine (N=49) or blinded treatment with another newer atypical antipsychotic not previously received in the trial (olanzapine [N=19], quetiapine [N=15], or risperidone [N=16 …
引用总数
2006200720082009201020112012201320142015201620172018201920202021202220232024399810278867610386557068516760514927289